Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway.
about
Targeting the adaptive molecular landscape of castration-resistant prostate cancerThe CXCL8-CXCR1/2 pathways in cancerA dual yet opposite growth-regulating function of miR-204 and its target XRN1 in prostate adenocarcinoma cells and neuroendocrine-like prostate cancer cellsN-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate CancerAggressive variants of castration-resistant prostate cancerThe molecular basis for ethnic variation and histological subtype differences in prostate cancer.Molecular pathology of prostate cancer revealed by next-generation sequencing: opportunities for genome-based personalized therapy.CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy.Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatmentTranslational and clinical implications of the genetic landscape of prostate cancer.Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells.Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.Adaptation or selection--mechanisms of castration-resistant prostate cancer.Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation.Targeting neuroendocrine prostate cancer: molecular and clinical perspectives.Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.FOXA1 inhibits prostate cancer neuroendocrine differentiation.Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.Emerging trends in the evaluation and management of small cell prostate cancer: a clinical and molecular perspective.Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.Neuroendocrine differentiation of prostate cancer.Establishment of a neuroendocrine prostate cancer model driven by the RNA splicing factor SRRM4.p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma.Biology and evolution of poorly differentiated neuroendocrine tumors.MicroRNA-652 induces NED in LNCaP and EMT in PC3 prostate cancer cells.The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.Impact of p53 and PDGFR-β Expression on Metastasis and Prognosis of Patients with Pancreatic Cancer.Development of Neuroendocrine Prostate Cancers by the Ser/Arg Repetitive Matrix 4-Mediated RNA Splicing Network.Mutant allele quantification reveals a genetic basis for TP53 mutation-driven castration resistance in prostate cancer cells
P2860
Q27022821-7DF6D458-D8F3-4D2F-A0F8-27D8DEBFE507Q28075994-8391289F-182C-466C-97CE-8B30B43AC461Q28573536-C9ECAC57-D93F-4E36-BF91-5BB8001D1236Q28771715-16A32208-97E0-429D-8D4F-B3C6E2630ECBQ33693256-E1E4EC41-ABD7-4700-9E4B-7E5E8051B769Q33835864-55FDE663-91FC-46F3-8DB5-791024F70086Q33862462-77CDFF82-593E-4BEE-A7D0-E11E14F7ADBFQ35178381-972C7C88-F23D-4F7E-8A8E-01ED67C3C65DQ35555483-5BB78628-4B13-48A5-9FEA-71FBFB039D46Q36131601-FDE113AA-8AE3-48F2-B61E-77A1183D6048Q37270512-B541831A-157D-4A16-9E13-82F717FCB41EQ37394982-BBE35080-DEDB-4D2F-809C-BD50E610CD07Q37709535-4C9C01EA-0965-4617-B3C6-2E44867E0255Q38068116-6463729C-7C4B-40CC-8800-3BEEC1E862AFQ38192816-EE6556BC-C191-475A-8DDF-3AA8474CA4E0Q38362686-2026E456-141C-4679-A561-DDA524405D8EQ38768101-D0481C5F-02B4-4108-8162-0036D0567549Q38893882-4561CEAD-B1B1-44E4-82D0-48C158E97963Q38923020-03A260F2-F136-48A9-AA3D-B9A5D8A22278Q38930155-D5110A86-E9AB-4909-BBFA-AAA60AC3EB04Q39044979-BA2B233C-8914-41E8-8C78-0A563447895BQ39179651-56FF6266-2DBC-40E3-ACBA-B5E042759590Q42071191-1F62DDEC-0374-40C3-9550-DF0D4E89E3E7Q43197266-F37232AB-B7A5-4B67-9E6C-EDF620674A08Q48320507-D60E0B7C-BC29-4CD1-BC4E-9829BC2B9DCBQ52714356-E761A141-71F3-4F51-B231-56E3DCA183A1Q53682879-CA47C029-9245-4D8F-86EE-F2D5701B3BCBQ54210630-86F92C3B-736D-4774-A8E3-1183764CA89EQ55171826-AA349BEC-924E-40C1-8288-52BFA71E7EA4Q58731111-369478ED-B2B2-4097-A052-338A6D00C2AC
P2860
Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Pathogenesis of prostatic smal ...... activation of the P53 pathway.
@ast
Pathogenesis of prostatic smal ...... activation of the P53 pathway.
@en
type
label
Pathogenesis of prostatic smal ...... activation of the P53 pathway.
@ast
Pathogenesis of prostatic smal ...... activation of the P53 pathway.
@en
prefLabel
Pathogenesis of prostatic smal ...... activation of the P53 pathway.
@ast
Pathogenesis of prostatic smal ...... activation of the P53 pathway.
@en
P2093
P2860
P356
P1476
Pathogenesis of prostatic smal ...... activation of the P53 pathway.
@en
P2093
Adeboye O Osunkoya
Chaozhao Liang
Chengyu Wu
Clara E Magyar
Hongbing Chen
Jiaoti Huang
Jorge L Yao
Liang Cheng
Steven Shen
P2860
P304
P356
10.1530/ERC-11-0368
P577
2012-05-24T00:00:00Z